3,749 reports of this reaction
6.2% of all BELIMUMAB reports
#2 most reported adverse reaction
SYSTEMIC LUPUS ERYTHEMATOSUS is the #2 most commonly reported adverse reaction for BELIMUMAB, manufactured by GlaxoSmithKline LLC. There are 3,749 FDA adverse event reports linking BELIMUMAB to SYSTEMIC LUPUS ERYTHEMATOSUS. This represents approximately 6.2% of all 60,128 adverse event reports for this drug.
Patients taking BELIMUMAB who experience systemic lupus erythematosus should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SYSTEMIC LUPUS ERYTHEMATOSUS is moderately reported among BELIMUMAB users, representing a notable but not dominant share of adverse events.
In addition to systemic lupus erythematosus, the following adverse reactions have been reported for BELIMUMAB:
The following drugs have also been linked to systemic lupus erythematosus in FDA adverse event reports:
SYSTEMIC LUPUS ERYTHEMATOSUS has been reported as an adverse event in 3,749 FDA reports for BELIMUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
SYSTEMIC LUPUS ERYTHEMATOSUS accounts for approximately 6.2% of all adverse event reports for BELIMUMAB, making it one of the most commonly reported side effect.
If you experience systemic lupus erythematosus while taking BELIMUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.